When Product Shortages Spread Into Their Alternatives

A shortage does not always remain inside one product.

Sometimes demand moves.

Customers cannot obtain the product they normally use.

They look for an alternative.

In healthcare, clinicians and pharmacists may consider another appropriate formulation.

When enough demand shifts at the same time, pressure can begin appearing in the alternative market too.

A supply problem that begins with one product can therefore become a wider market problem.

The U.S. Estrogen Market Shows the Mechanism

Reuters reported on 28 October that difficulties obtaining estrogen patches in the United States were beginning to influence demand for other forms of hormone therapy.

Patients and clinicians were turning to alternatives including gels, creams, injections, and vaginal products when clinically appropriate.

Pharmacists reported shortages or backorders in some injectable and vaginal products.

Cost Plus Drugs told Reuters that demand for many products on its platform had increased approximately fivefold to tenfold, although it had largely maintained inventory.

The original access problem was therefore beginning to influence other products within the same treatment category.

Source: Reuters, 28 October 2026.

The FDA Says Patch Supply Has Increased Substantially

The supply problem is not simply one of declining production.

In September, the U.S. Food and Drug Administration said supply of FDA-approved estradiol transdermal patches had nearly doubled during the previous year.

But demand had increased even faster.

The FDA has been working with all six U.S. manufacturers to increase availability.

The agency has also clarified that estradiol patches remain available, although particular products or brands can be difficult to obtain at some pharmacies or locations.

Source: U.S. Food and Drug Administration, 3 September 2026.

Demand Can Move Faster Than Manufacturing Capacity

The timing difference is important.

A patient experiencing difficulty finding one formulation can discuss another treatment option relatively quickly with a pharmacist or healthcare provider.

A manufacturer cannot expand regulated pharmaceutical production equally quickly.

The FDA says manufacturers are adding production shifts, increasing batch sizes, expanding production capacity, and adding specialized equipment and manufacturing lines.

Some measures can increase supply relatively quickly.

Larger expansions take longer because transdermal patches require specialized equipment and processes.

Source: U.S. Food and Drug Administration, September 2026.

A Shortage Can Spread Through Demand Without One Shared Supply Failure

Several products can become difficult to obtain without sharing exactly the same upstream problem.

Reuters reported that industry specialists did not see clear evidence of one broad raw-material shortage affecting the entire estrogen category.

Supply-chain disruptions can still contribute.

But rising demand and switching between formulations can create additional pressure on their own.

Scarcity can therefore travel through customer behaviour as well as through physical supply-chain failures.

Source: Reuters, 28 October 2026.

Medical Alternatives Are Not Perfect Substitutes

Pharmaceutical substitution is more complicated than choosing another ordinary consumer product.

Different formulations can involve different doses, administration methods, absorption, clinical considerations, and prescribing requirements.

The FDA advises patients experiencing difficulty obtaining their usual patch to speak with a pharmacist or healthcare provider.

Patients should not stop or change medication independently.

This means alternative products can expand treatment options, but they are not automatically interchangeable for every patient.

Existing Inventory Absorbs the First Increase in Demand

When customers move toward alternative products, manufacturers do not immediately create the additional units.

Existing inventories absorb the change first.

Distributors hold stock.

Pharmacies hold stock.

Suppliers hold stock.

That inventory can provide an important buffer.

But the buffer is finite.

If redirected demand persists, stocks can tighten before production has enough time to expand.

Pharmaceutical Capacity Takes Time to Expand

Medicine manufacturing is intentionally subject to strict quality requirements.

Additional production can require specialized equipment, qualified processes, quality controls, testing, regulatory submissions, and other manufacturing requirements.

These controls protect patients.

They also mean that pharmaceutical production cannot necessarily respond immediately to a sudden increase in demand.

The relevant challenge is therefore expanding supply without compromising product quality or patient safety.

Manufacturers Are Already Increasing Supply

The current situation is not static.

Viatris told Reuters that it had added another production shift at its Vermont facility, taking operations to around-the-clock production.

The company is also investing in additional equipment and another production line to expand longer-term capacity.

Other manufacturers have also reported significant demand growth and efforts to increase production.

The market is therefore adapting.

The difficulty is that adaptation takes time.

Sources: Reuters; U.S. Food and Drug Administration, 2026.

A New Approval Can Expand Options Without Immediately Expanding Supply

The FDA announced on 20 October that it had approved the first generic of Climara Pro.

The approval date was 19 October 2026.

The product is a once-weekly estradiol and levonorgestrel transdermal system.

The approval expands the number of authorized treatment products.

But regulatory approval and commercial availability are separate stages.

The FDA itself notes that an approved generic is not necessarily available immediately after approval.

Source: U.S. Food and Drug Administration, 19-20 October 2026.

The Market Is Also Facing Higher Overall Demand

Substitution is not the only source of pressure.

Overall demand for menopause hormone therapy has also increased.

The FDA says more women have been seeking treatment following changes to hormone-therapy labeling in November 2025.

This means manufacturers are responding to two pressures at the same time.

More people are entering the treatment market.

And some existing patients are moving between formulations.

Production capacity based on earlier demand patterns can consequently come under greater pressure.

Low-Margin Medicines Can Be Harder to Expand Rapidly

Economics also matter.

Reuters reported earlier in 2026 that estradiol patches are generic medicines with relatively low profit margins.

Thin margins can weaken incentives to maintain large amounts of unused production capacity during normal periods.

When demand then rises quickly, manufacturers can face a difficult transition between historical capacity and the new level of demand.

Source: Reuters, 9 April 2026.

Substitution Can Create New Concentration

Alternatives can make a supply system more resilient.

But if large numbers of customers move toward only a small number of alternative products or suppliers, new pressure can emerge.

The response to one shortage can therefore create greater dependence elsewhere in the market.

This is why the existence of an alternative does not by itself guarantee that the alternative market can absorb a large demand shift.

The Pattern Extends Beyond Pharmaceuticals

The underlying supply-chain mechanism is not unique to medicine.

Similar effects can occur with food ingredients, semiconductors, industrial components, energy sources, and transport modes.

When one option becomes scarce, users move toward another.

If the alternative has enough capacity, the system absorbs the change.

If it does not, the pressure can spread.

Shortage Monitoring Needs to Look Beyond the Original Product

A product shortage can change demand elsewhere before new manufacturing capacity becomes available.

This means market conditions around substitutes can become relevant even when their original supply chains were not the source of the disruption.

Demand behaviour can therefore become part of supply-chain dynamics.

Understanding scarcity requires watching not only where supply failed, but also where demand moved.

Conclusion

The current U.S. estrogen market shows how a supply constraint can extend beyond the product where it first appears.

Access difficulties affecting patches have encouraged some patients and clinicians to consider other formulations.

Demand has consequently increased for some alternative products, while pharmacists have reported additional backorders and shortages.

Manufacturers are expanding production, and the FDA is working with suppliers to increase availability.

New product approvals can also expand treatment options.

But manufacturing capacity takes longer to expand than customers can change what they seek.

That timing difference is what allows scarcity to move from one product into another.

The lesson is not that every shortage will spread.

It is that alternatives provide real resilience only when their supply systems can accommodate the additional demand.

Once redirected demand grows faster than alternative supply can respond, scarcity can stop being a problem of one product and become a wider market-capacity problem.